Lipocine Inc Common (LPCN) 8.39 $LPCN
Lipocine reports 1Q loss
Automated Insights - Mon May 09, 3:47PM CDT
SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Monday reported a loss of $7 million in its first quarter.
LPCN: 8.39 (-0.71)
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO(TM) ("LPCN 1021"
at the 2016 American Urological Association Annual Meeting
GlobeNewswire - Mon May 02, 7:00AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO(TM) ("LPCN 1021" , will be presented in poster and podium presentations at the 2016 American Urological Association Annual Meeting being held May 6-10 in San Diego, CA. TLANDO is an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
LPCN: 8.39 (-0.71)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 6.71 (-0.44), VNDA: 10.79 (-0.19), LPCN: 8.39 (-0.71), CHMA: 2.91 (-0.23)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at ENDO 2016 in Boston, MA.
LPCN: 8.39 (-0.71)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at the American Society of Andrology 41 Annual Meeting in New Orleans, LA.
LPCN: 8.39 (-0.71)
Lipocine Announces Financial and Operational Results for the Full Year of 2015
GlobeNewswire - Thu Mar 10, 3:30PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015.
LPCN: 8.39 (-0.71)
Lipocine to Present at 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 7:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28 Annual Roth Conference on Tuesday, March 15, 2016 at 8:00 a.m. PT.
LPCN: 8.39 (-0.71)
Labor and Delivery Global Clinical Trials Review, H2, 2015 - Key Vendors: Lipocine Inc., Alliance Pharma Plc & Christiana Care Health System - Research and Markets
BusinessWire - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2l5cl9/labor_and) has announced the addition of the "Labor And Delivery Global Clinical Trials Review, H2, 2015" report to their offering.
LPCN: 8.39 (-0.71)
Male Hypogonadism Pipeline Review, H2 2015 - 15 Companies & 16 Drug Profiles
M2 - Tue Jan 05, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/7r9g86/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Antares Pharma, Inc. - BIOCAD - Clarus Therapeutics, Inc. - Diurnal Limited - EndoCeutics, Inc. - Ferring International Center S.A. - Forendo Pharma Limited - Lipocine Inc. - M et P Pharma AG - Merck & Co., Inc. - Mereo Biopharma Group Limited - Millennium Pharmaceuticals, Inc. - Monosol Rx, LLC - Pantarhei Bioscience BV - Repros Therapeutics Inc. Drug Profiles - BGS-649 - corifollitropin alfa - enclomiphene - fispemifene - follitropin alfa - Kisspeptin-10 - Libidua - LPCN-1111 - MSS-722 - T-2 - TAK-448 - TBS-1 - Testavan - testosterone - testosterone enanthate - testosterone undecanoate For more information visit http://www.researchandmarkets.com/research/7r...pogonadism
MRK: 56.83 (-0.35), LPCN: 8.39 (-0.71), ATRS: 1.04 (-0.05)
Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy
GlobeNewswire - Mon Jan 04, 8:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical study for LPCN 1111, a novel testosterone replacement therapy ("TRT" product candidate. The primary objectives of the study will be to determine the optimal dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses of LPCN 1111 in hypogonadal males.
LPCN: 8.39 (-0.71)
Market Influences That Drive Equities Forward - New Research on Lipocine, Imprivata, Ardelyx and Vital Therapies
ACCESSWIRE - Tue Dec 15, 6:51AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc. (NASDAQ: LPCN), Imprivata Inc. (NYSE: IMPR), Ardelyx Inc. (NASDAQ: ARDX) and Vital Therapies Inc. (NASDAQ: VTL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
IMPR: 13.41 (-0.05), VTL: 7.60 (-0.22), LPCN: 8.39 (-0.71), ARDX: 8.09 (-0.57)
Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 8:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 12:50 p.m. ET.
LPCN: 8.39 (-0.71)
Analyst Insights behind Price Movement - Research on Lipocine, Syneron Medical, Republic Airways and Accretive Health
ACCESSWIRE - Tue Nov 24, 7:32AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc (NASDAQ: LPCN), Syneron Medical Ltd. (NASDAQ: ELOS), Republic Airways Holdings Inc. (NASDAQ: RJET) and Accretive Health, Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ELOS: 7.20 (-0.04), RJET: 1.31 (+0.02), LPCN: 8.39 (-0.71)
Covered Call Alerts For SolarCity, SunEdison, 3D Systems, Lipocine Inc. and Kandi Technologies Released By InvestorsObserver
PR Newswire - Mon Nov 16, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SCTY, SUNE, DDD, LPCN and KNDI.
KNDI: 7.12 (-0.26), SCTY: 21.26 (-1.40), DDD: 12.46 (-0.62), SUNE: 0.34 (unch), LPCN: 8.39 (-0.71)
Origins of Technical Movement, Pricing Tomorrow - Research on Lipocine, Syneron Medical, Republic Airways Holdings, and Accretive Health
ACCESSWIRE - Mon Nov 16, 7:31AM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc. (NASDAQ: LPCN), Syneron Medical Ltd (NASDAQ: ELOS), Republic Airways Holdings Inc. (NASDAQ: RJET) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ELOS: 7.20 (-0.04), RJET: 1.31 (+0.02), LPCN: 8.39 (-0.71)
Lipocine Adopts Stockholder Rights Plan
GlobeNewswire - Fri Nov 13, 3:00PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a stockholder rights plan designed to deter coercive takeover tactics, including the accumulation of shares in the open market or through private transactions and to prevent an acquirer from gaining control of without offering a fair price to all of the its stockholders.
LPCN: 8.39 (-0.71)
Lipocine Announces Financial and Operational Results for the Third Quarter of 2015
GlobeNewswire - Thu Nov 12, 3:10PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well as recent operational highlights.
LPCN: 8.39 (-0.71)
Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
GlobeNewswire - Thu Nov 12, 3:10PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA" has assigned a Prescription Drug User Fee Act ("PDUFA" goal date of June 28, 2016 for completion of the review of the New Drug Application ("NDA" for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT" in adult males for conditions associated with a deficiency or absence of endogenous testosterone ("hypogonadism" . Additionally, the 74-day filing communication letter did not mention a need to convene an Advisory Committee for advice on the NDA for LPCN 1021 and we confirmed in subsequent communication with the FDA that an Advisory Committee is not planned.
LPCN: 8.39 (-0.71)
Lipocine reports 1Q loss
Automated Insights - Mon May 09, 3:47PM CDT
SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Monday reported a loss of $7 million in its first quarter.
LPCN: 8.39 (-0.71)
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO(TM) ("LPCN 1021"
at the 2016 American Urological Association Annual Meeting GlobeNewswire - Mon May 02, 7:00AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO(TM) ("LPCN 1021"
, will be presented in poster and podium presentations at the 2016 American Urological Association Annual Meeting being held May 6-10 in San Diego, CA. TLANDO is an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. LPCN: 8.39 (-0.71)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 6.71 (-0.44), VNDA: 10.79 (-0.19), LPCN: 8.39 (-0.71), CHMA: 2.91 (-0.23)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT"
product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at ENDO 2016 in Boston, MA. LPCN: 8.39 (-0.71)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT"
product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at the American Society of Andrology 41 Annual Meeting in New Orleans, LA. LPCN: 8.39 (-0.71)
Lipocine Announces Financial and Operational Results for the Full Year of 2015
GlobeNewswire - Thu Mar 10, 3:30PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015.
LPCN: 8.39 (-0.71)
Lipocine to Present at 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 7:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28 Annual Roth Conference on Tuesday, March 15, 2016 at 8:00 a.m. PT.
LPCN: 8.39 (-0.71)
Labor and Delivery Global Clinical Trials Review, H2, 2015 - Key Vendors: Lipocine Inc., Alliance Pharma Plc & Christiana Care Health System - Research and Markets
BusinessWire - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2l5cl9/labor_and) has announced the addition of the "Labor And Delivery Global Clinical Trials Review, H2, 2015" report to their offering.
LPCN: 8.39 (-0.71)
Male Hypogonadism Pipeline Review, H2 2015 - 15 Companies & 16 Drug Profiles
M2 - Tue Jan 05, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/7r9g86/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Antares Pharma, Inc. - BIOCAD - Clarus Therapeutics, Inc. - Diurnal Limited - EndoCeutics, Inc. - Ferring International Center S.A. - Forendo Pharma Limited - Lipocine Inc. - M et P Pharma AG - Merck & Co., Inc. - Mereo Biopharma Group Limited - Millennium Pharmaceuticals, Inc. - Monosol Rx, LLC - Pantarhei Bioscience BV - Repros Therapeutics Inc. Drug Profiles - BGS-649 - corifollitropin alfa - enclomiphene - fispemifene - follitropin alfa - Kisspeptin-10 - Libidua - LPCN-1111 - MSS-722 - T-2 - TAK-448 - TBS-1 - Testavan - testosterone - testosterone enanthate - testosterone undecanoate For more information visit http://www.researchandmarkets.com/research/7r...pogonadism
MRK: 56.83 (-0.35), LPCN: 8.39 (-0.71), ATRS: 1.04 (-0.05)
Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy
GlobeNewswire - Mon Jan 04, 8:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical study for LPCN 1111, a novel testosterone replacement therapy ("TRT"
product candidate. The primary objectives of the study will be to determine the optimal dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses of LPCN 1111 in hypogonadal males. LPCN: 8.39 (-0.71)
Market Influences That Drive Equities Forward - New Research on Lipocine, Imprivata, Ardelyx and Vital Therapies
ACCESSWIRE - Tue Dec 15, 6:51AM CST
NEW YORK, NY / ACCESSWIRE / December 15, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc. (NASDAQ: LPCN), Imprivata Inc. (NYSE: IMPR), Ardelyx Inc. (NASDAQ: ARDX) and Vital Therapies Inc. (NASDAQ: VTL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
IMPR: 13.41 (-0.05), VTL: 7.60 (-0.22), LPCN: 8.39 (-0.71), ARDX: 8.09 (-0.57)
Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 8:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 27Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 12:50 p.m. ET.
LPCN: 8.39 (-0.71)
Analyst Insights behind Price Movement - Research on Lipocine, Syneron Medical, Republic Airways and Accretive Health
ACCESSWIRE - Tue Nov 24, 7:32AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc (NASDAQ: LPCN), Syneron Medical Ltd. (NASDAQ: ELOS), Republic Airways Holdings Inc. (NASDAQ: RJET) and Accretive Health, Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ELOS: 7.20 (-0.04), RJET: 1.31 (+0.02), LPCN: 8.39 (-0.71)
Covered Call Alerts For SolarCity, SunEdison, 3D Systems, Lipocine Inc. and Kandi Technologies Released By InvestorsObserver
PR Newswire - Mon Nov 16, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SCTY, SUNE, DDD, LPCN and KNDI.
KNDI: 7.12 (-0.26), SCTY: 21.26 (-1.40), DDD: 12.46 (-0.62), SUNE: 0.34 (unch), LPCN: 8.39 (-0.71)
Origins of Technical Movement, Pricing Tomorrow - Research on Lipocine, Syneron Medical, Republic Airways Holdings, and Accretive Health
ACCESSWIRE - Mon Nov 16, 7:31AM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lipocine Inc. (NASDAQ: LPCN), Syneron Medical Ltd (NASDAQ: ELOS), Republic Airways Holdings Inc. (NASDAQ: RJET) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ELOS: 7.20 (-0.04), RJET: 1.31 (+0.02), LPCN: 8.39 (-0.71)
Lipocine Adopts Stockholder Rights Plan
GlobeNewswire - Fri Nov 13, 3:00PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a stockholder rights plan designed to deter coercive takeover tactics, including the accumulation of shares in the open market or through private transactions and to prevent an acquirer from gaining control of without offering a fair price to all of the its stockholders.
LPCN: 8.39 (-0.71)
Lipocine Announces Financial and Operational Results for the Third Quarter of 2015
GlobeNewswire - Thu Nov 12, 3:10PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as well as recent operational highlights.
LPCN: 8.39 (-0.71)
Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
GlobeNewswire - Thu Nov 12, 3:10PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA"
has assigned a Prescription Drug User Fee Act ("PDUFA" goal date of June 28, 2016 for completion of the review of the New Drug Application ("NDA" for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT" in adult males for conditions associated with a deficiency or absence of endogenous testosterone ("hypogonadism" . Additionally, the 74-day filing communication letter did not mention a need to convene an Advisory Committee for advice on the NDA for LPCN 1021 and we confirmed in subsequent communication with the FDA that an Advisory Committee is not planned. LPCN: 8.39 (-0.71)
